Mga Batayang Estadistika
| LEI | 549300FQIORB6GZCYT15 |
| CIK | 70487 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to National Research Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Comm |
|
| August 28, 2025 |
NRC HEALTH ANNOUNCES SHANE HARRISON AS CHIEF FINANCIAL OFFICER Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com NRC HEALTH ANNOUNCES SHANE HARRISON AS CHIEF FINANCIAL OFFICER LINCOLN, Nebraska, August 28, 2025 — (Business Wire) – National Research Corporation (NASDAQ: NRC), doing business as NRC Health, a publicly-traded leader in healthcare experience, is pleased to announce the appointment of Shane Harrison as |
|
| August 8, 2025 |
Form of Incentive Stock Award Notice, Bonus, and Severance Agreement Exhibit 10.2 NATIONAL RESEARCH CORPORATION INCENTIVE STOCK AWARD NOTICE, BONUS, AND SEVERANCE AGREEMENT GRANTEE: [Name] (“you” or “Executive”) TYPE AND AMOUNT OF AWARD: [Number] Shares of Common Stock of National Research Corporation (the “Shares”) DATE OF GRANT: [Date] (the “Grant Date”) 1. Grant of Award. This Incentive Stock Award Notice, Bonus, and Severance Agreement (this “Agreement”) is mad |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nati |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commis |
|
| July 28, 2025 |
Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com NRC HEALTH ANNOUNCES SECOND QUARTER 2025 RESULTS Reports third consecutive quarter of sequential TRCV Growth LINCOLN, Nebraska, July 28, 2025 — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2025. CEO Statement Trent S. Green, Chief Executive O |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commissi |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nat |
|
| May 9, 2025 |
Trent Green Offer Letter dated February 26, 2025 Exhibit 10.2 February 26, 2025 Trent Green Dear Trent, On behalf of NRC Health, we are pleased to offer you the position of Chief Executive Officer and member of NRC’s Board of Directors, effective as of your start date. Each of our Board members is excited to support your leadership of our organization and looks forward to the contributions you will make in this role. In accepting this offer, you |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commi |
|
| April 28, 2025 |
NRC HEALTH ANNOUNCES FIRST QUARTER RESULTS EXHIBIT 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Michelle Bachman 402-475-2525 NRC HEALTH ANNOUNCES FIRST QUARTER RESULTS LINCOLN, Nebraska, April 28, 2025 — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: ■ Total Recurring Value Contr |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2025 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commi |
|
| April 10, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commis |
|
| March 17, 2025 |
Exhibit 19 NATIONAL RESEARCH CORPORATION INSIDER TRADING POLICY Effective Date: March 14, 2025 This Insider Trading Policy (this “Policy”) consists of eight sections: ■ Section 1 provides an overview; ■ Section 2 defines certain terms used herein; ■ Section 3 explains insider trading; ■ Section 4 sets forth the policies of National Research Corporation prohibiting insider trading; ■ Section 5 details the applicability to former associates; ■ Section 6 sets forth the confidentiality guidelines; ■ Section 7 explains the interpretation and amendment process to this Policy; and ■ Section 8 refers to the execution and return of a certificate of compliance. |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 National |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Co |
|
| March 4, 2025 |
1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Helen Hrdy 402-475-2525 NATIONAL RESEARCH CORPORATION APPOINTS TRENT GREEN AS CHIEF EXECUTIVE OFFICER LINCOLN, Nebraska, March 4, 2025 — National Research Corporation (NASDAQ: NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appo |
|
| February 10, 2025 |
Exhibit 10.1 CREDIT AGREEMENT among NATIONAL RESEARCH CORPORATION, as Borrower, CERTAIN FINANCIAL INSTITUTIONS, as Lenders and FIRST NATIONAL BANK OF OMAHA, as the Administrative Agent Dated as of February 6, 2025 THIS CREDIT AGREEMENT, dated as of February 6, 2025, is made and entered into by and among NATIONAL RESEARCH CORPORATION, a Delaware corporation (“Borrower”), EACH LENDER FROM TIME TO TI |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| January 27, 2025 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Michelle Bachman 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER RESULTS LINCOLN, Nebraska, January 27, 2025 — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2024 and other corporate developments. Financial Results |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| November 13, 2024 |
SC 13G/A 1 fp0090889-23sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 10)* NATIONAL RESEARCH CORP (Name of Issuer) Common Stock (Title of Class of Securities) 637372202 (CUSIP Number) September |
|
| November 8, 2024 |
Exhibit 10.1 THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) is made and entered into as of August 5, 2024, by and between NATIONAL RESEARCH CORPORATION, a Delaware corporation (“Borrower”), and FIRST NATIONAL BANK OF OMAHA, a national banking association (“Lender”). RECITALS : A. Borrower and Lender previous |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 |
|
| October 25, 2024 |
NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER RESULTS EX-99.1 2 ex736648.htm EXHIBIT 99.1 Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Linda A. Stacy Principal Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER RESULTS LINCOLN, Nebraska, October 25, 2024 — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the third quart |
|
| October 25, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2024 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nati |
|
| August 6, 2024 |
NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Linda A. Stacy Principal Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER RESULTS LINCOLN, Nebraska (August 6, 2024) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2024 and several other corporate |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commi |
|
| May 13, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commissi |
|
| May 9, 2024 |
Exhibit 10.1 Retirement Transition Agreement February 8, 2024 Kevin Karas 11003 Fairway Drive Omaha, NE 68136 Re: Retirement Transition Agreement Dear Kevin: This letter is the Retirement Transition Agreement (the “Agreement”) between you and National Research Corporation (the “Company”). Retirement Date You have provided notice to the Company’s Board of Directors on February 8, 2024 that you inte |
|
| May 9, 2024 |
Exhibit 10.2 Form of Option Award Notice NATIONAL RESEARCH CORPORATION 2006 EQUITY INCENTIVE PLAN AWARD NOTICE GRANTEE: [Associate name] TYPE OF AWARD: Non-qualified Stock Option NUMBER OF SHARES: [Number of shares] EXERCISE PRICE: [Price] per share DATE OF GRANT: [Date] (the “Grant Date”) EXPIRATION DATE: [Date] 1. Grant of Option. This Award Notice serves to notify you that National Research Cor |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nat |
|
| May 9, 2024 |
Form of Long-Term Incentive Award Notice and Severance Agreement Exhibit 10.3 Form of Long-Term Incentive Award Notice and Severance Agreement NATIONAL RESEARCH CORPORATION LONG-TERM INCENTIVE AWARD NOTICE AND SEVERANCE AGREEMENT GRANTEE: [Associate Name] TYPE OF AWARD: Cash AMOUNT: Up to $[Amount] (the “Maximum Amount”) DATE OF GRANT: [Date] (the “Grant Date”) 1. Grant of Award. This Award Notice and Severance Agreement (this “Agreement”) serves to notify you |
|
| May 7, 2024 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Linda A. Stacy Principal Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER RESULTS LINCOLN, Nebraska (May 7, 2024) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2024. CEO Commentary Michael Hays, Ch |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commissi |
|
| April 11, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 9)* NATIONAL RESEARCH CORP (Name of Issuer) Common Stock (Title of Class of Securities) 637372202 (CUSIP Number) February 29, 2024 (Date of Event which Requir |
|
| March 5, 2024 |
NRC / National Research Corporation / Common Property Trust - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 1) National Research Corporation (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Thomas Richardson Arnold & Porter Kaye Scholer LLP 601 Massachusetts Ave., NW Washington, D.C. 20001-3743 202-942-5171 (N |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 National Research Corporat |
|
| February 27, 2024 |
Subsidiary of National Research Corporation Exhibit 21 Subsidiary of National Research Corp. National Research Corporation’s subsidiary as of December 31, 2023 is listed below: Subsidiary Jurisdiction of organization National Research Corporation Canada Ontario |
|
| February 27, 2024 |
EXHIBIT 97 NATIONAL RESEARCH CORPORATION CLAWBACK POLICY 1. Introduction and Purpose 1.1 Introduction. This document sets forth the National Research Corporation Clawback Policy (the “Policy”), effective December 1, 2023 (the “Effective Date”). 1.2 Purpose. National Research Corporation (the “Company”) has established this Policy to appropriately align the interests of the executives of the Compan |
|
| February 13, 2024 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND CALENDAR YEAR 2023 RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND CALENDAR YEAR 2023 RESULTS LINCOLN, Nebraska (February 13, 2024) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2023. CEO |
|
| February 13, 2024 |
SC 13G/A 1 fp0086862-61sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 8)* NATIONAL RESEARCH CORP (Name of Issuer) Common Stock (Title of Class of Securities) 637372202 (CUSIP Number) December 31 |
|
| February 13, 2024 |
AGREEMENT JOINT FILING OF SCHEDULE 13G EX-1 2 fp0086862-61ex1.htm AGREEMENT JOINT FILING OF SCHEDULE 13G Kayne Anderson Rudnick Investment Management, LLC (an investment adviser registered under the Investment Advisers Act of 1940), and Virtus Investment Advisers, Inc. (an investment adviser registered under the Investment Advisers Act of 1940) and Virtus Equity Trust (on behalf of Virtus KAR Small-Cap Growth Fund), a Delaware statutor |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| January 17, 2024 |
NATIONAL RESEARCH CORPORATION ELEVATES LEADERSHIP TEAM TO SEIZE GROWTH OPPORTUNITY Exhibit 99 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth. |
|
| January 4, 2024 |
NRCIA / National Research Corp. / Amandla MK Trust - SCHEDULE 13D/A Activist Investment SC 13D/A 1 schedule13da.htm SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 8) National Research Corporation (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Patrick E. Beans Amandla LLC 709 Pier 2 Lincoln, NE 68528 402-440-2768 (Name |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Co |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 |
|
| November 8, 2023 |
Exhibit 99.2 Kevin: Thank you, , and welcome everyone to National Research Corporation’s 2023 third quarter earnings call. My name is Kevin Karas, the company’s CFO, and joining me on the call today is Linda Stacy, our Vice President of Finance. Before we continue, I would ask Linda to review conditions related to any forward-looking statements that may be made as part of today’s call. Linda. Lind |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| November 8, 2023 |
NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2023 RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2023 RESULTS LINCOLN, Nebraska (November 7, 2023) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the third quarter 2023. Regarding the Company’s 2 |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nati |
|
| August 4, 2023 |
Exhibit 10.1 SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) is made and entered into as of June 16, 2023, by and between NATIONAL RESEARCH CORPORATION, a Delaware corporation (“Borrower”), and FIRST NATIONAL BANK OF OMAHA, a national banking association (“Lender”). R E C I T A L S: A. Borrower and Lender p |
|
| August 3, 2023 |
NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2023 RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2023 RESULTS LINCOLN, Nebraska (August 1, 2023) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2023. Regarding the Company’s 2 |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commi |
|
| August 3, 2023 |
Exhibit 99.2 Kevin: Thank you, , and welcome everyone to National Research Corporation’s 2023 second quarter earnings call. My name is Kevin Karas, the company’s CFO, and joining me on the call today is Linda Stacy, our Vice President of Finance. Before we continue, I would ask Linda to review conditions related to any forward-looking statements that may be made as part of today’s call. Linda. Lin |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commiss |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nat |
|
| May 4, 2023 |
Exhibit 99.2 Kevin: Thank you, , and welcome everyone to National Research Corporation’s 2023 first quarter earnings call. My name is Kevin Karas, the company’s CFO, and joining me on the call today is Linda Stacy, our Vice President of Finance. Before we continue, I would ask Linda to review conditions related to any forward-looking statements that may be made as part of today’s call. Linda. Lind |
|
| May 4, 2023 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2023 RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2023 RESULTS LINCOLN, Nebraska (May 2, 2023) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2023. Regarding the Company’s 2023 f |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commissi |
|
| April 28, 2023 |
As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. |
|
| April 28, 2023 |
As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. |
|
| April 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| March 3, 2023 |
Subsidiary of National Research Corporation Exhibit 21 Subsidiary of National Research Corp. National Research Corporation’s subsidiary as of December 31, 2022 is listed below: Subsidiary Jurisdiction of organization National Research Corporation Canada Ontario |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 National |
|
| February 16, 2023 |
Exhibit 99.2 Kevin: Thank you, , and welcome everyone to National Research Corporation’s 2022 fourth quarter earnings call. My name is Kevin Karas, the company’s CFO, and joining me on the call today is Linda Stacy, our Vice President of Finance. Before we continue, I would ask Linda to review conditions related to any forward-looking statements that may be made as part of today’s call. Linda. Lin |
|
| February 16, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Co |
|
| February 16, 2023 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND CALENDAR YEAR 2022 RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND CALENDAR YEAR 2022 RESULTS LINCOLN, Nebraska (February 14, 2023) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter and calend |
|
| February 14, 2023 |
SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* NATIONAL RESEARCH CORP (Name of Issuer) Common Stock (Title of Class of Securities) 637372202 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2023 |
AGREEMENT JOINT FILING OF SCHEDULE 13G EX-99.2 2 ex992.htm EX-99.2 AGREEMENT JOINT FILING OF SCHEDULE 13G Kayne Anderson Rudnick Investment Management, LLC (an investment adviser registered under the Investment Advisers Act of 1940), and Virtus Investment Advisers, Inc. (an investment adviser registered under the Investment Advisers Act of 1940) and Virtus Equity Trust (on behalf of Virtus KAR Small-Cap Growth Fund), a Delaware statuto |
|
| November 4, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this ?Amendment?) is made and entered into as of September 30, 2022, by and between NATIONAL RESEARCH CORPORATION, a Delaware corporation (?Borrower?), and FIRST NATIONAL BANK OF OMAHA, a national banking association (?Lender?). R E C I T A L S: A. Borrower and Lende |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 |
|
| November 3, 2022 |
Exhibit 99.2 Kevin: Thank you, , and welcome everyone to National Research Corporation?s 2022 third quarter earnings call. My name is Kevin Karas, the company?s CFO, and joining me on the call today is Linda Stacy, our Vice President of Finance. Before we continue, I would ask Linda to review conditions related to any forward-looking statements that may be made as part of today?s call. Linda. Lind |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| November 3, 2022 |
NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2022 RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2022 RESULTS LINCOLN, Nebraska (November 1, 2022) ? National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the third quarter 2022. Regarding the Company?s 2 |
|
| November 1, 2022 |
NRCIA / National Research Corp. / Amandla MK Trust - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 7) National Research Corporation (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Patrick E. Beans Amandla LLC 709 Pier 2 Lincoln, NE 68528 402-440-2768 (Name, Address and Telephone Number of Person Au |
|
| October 3, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (C |
|
| September 14, 2022 |
1 800 388 4264 nrchealth.com September 14, 2022 VIA EDGAR CORRESPONDENCE U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Trade & Services 100 F Street, N.E. Washington, D.C. 20549 Re: National Research Corporation Form 10-K for the Year Ended December 31, 2021 Filed March 4, 2022 File No. 01-35929 Ladies and Gentlemen: Set forth below are the responses of Nationa |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nati |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commi |
|
| August 4, 2022 |
NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2022 RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2022 RESULTS LINCOLN, Nebraska (August 2, 2022) ? National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2022. Q2 2022 financial results |
|
| August 4, 2022 |
Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation?s 2022 second quarter earnings call. My name is Mike Hays, the Company?s CEO, and joining me on the call today is Kevin Karas, our Chief Financial Officer. Before we continue, I would ask Kevin to review conditions related to any forward-looking statements that may be made as part of today?s call. Kevin. Kevin: T |
|
| June 13, 2022 |
NRCIA / National Research Corp. / Amandla MK Trust - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 6) National Research Corporation (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Patrick E. Beans Amandla LLC 709 Pier 2 Lincoln, NE 68528 402-440-2768 (Name, Address and Telephone Number of Person Au |
|
| May 23, 2022 |
NATIONAL RESEARCH CORPORATION ANNOUNCES QUARTERLY DIVIDEND AND STOCK REPURCHASE AUTHORIZATION Exhibit 99 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth. |
|
| May 23, 2022 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commiss |
|
| May 20, 2022 |
National Research Corporation Announces Appointment to Board of Directors Exhibit 99 National Research Corporation Announces Appointment to Board of Directors Microsoft Executive Parul Bhandari Brings Digital Transformation Expertise to Board LINCOLN, Neb. |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commiss |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nat |
|
| May 5, 2022 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2022 RESULTS Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2022 RESULTS LINCOLN, Nebraska (May 3, 2022) ? National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2022. Q1 2022 financial results comp |
|
| May 5, 2022 |
Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation?s 2022 first quarter earnings call. My name is Mike Hays, the Company?s CEO, and joining me on the call today is Kevin Karas, our Chief Financial Officer. Before we continue, I would ask Kevin to review conditions related to any forward-looking statements that may be made as part of today?s call. Kevin. Kevin: Th |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commissi |
|
| April 7, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| March 4, 2022 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, National Research Corporation (the ?Company,? ?we,? ?us? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), our common stock, par value $.001 (?Common Stock?). |
|
| March 4, 2022 |
Subsidiary of National Research Corporation Exhibit 21 Subsidiary of National Research Corp. National Research Corporation?s subsidiary as of December 31, 2021 is listed below: Subsidiary Jurisdiction of organization National Research Corporation Canada Ontario |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 National |
|
| February 11, 2022 |
AGREEMENT JOINT FILING OF SCHEDULE 13G AGREEMENT JOINT FILING OF SCHEDULE 13G Kayne Anderson Rudnick Investment Management, LLC (an investment adviser registered under the Investment Advisers Act of 1940), and Virtus Investment Advisers, Inc. |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* NATIONAL RESEARCH CORP (Name of Issuer) Common Stock (Title of Class of Securities) 637372202 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2022 |
Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation?s 2021 fourth quarter and year-end earnings call. My name is Mike Hays, the Company?s CEO, and joining me on the call today is Kevin Karas, our Chief Financial Officer. Before we continue, I would ask Kevin to review conditions related to any forward-looking statements that may be made as part of today?s call. Ke |
|
| February 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2022 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| February 10, 2022 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND CALENDAR YEAR 2021 RESULTS Exhibit 99.1 1245 ?Q? Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND CALENDAR YEAR 2021 RESULTS LINCOLN, Nebraska (February 8, 2022) ? National Research Corporation (NASDAQ:NRC) today announced results for the fourth quarter of 2021. Q4 2021 financial results comp |
|
| December 8, 2021 |
NRCIA / National Research Corp. / Amandla MK Trust - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 5) National Research Corporation (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Patrick E. Beans Amandla LLC 709 Pier 2 Lincoln, NE 68528 402-440-2768 (Name, Address and Telephone Number of Person Au |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 |
|
| November 5, 2021 |
Exhibit 10.1 FORM OF GRANT USED IN CONNECTION WITH THE NATIONAL RESEARCH CORPORATION 2004 NON-EMPLOYEE DIRECTOR STOCK PLAN, AS AMENDED [Director name] Re: Stock Option Grant National Research Corporation Director Stock Plan This letter is to confirm that on [date], you were automatically granted a nonqualified stock option to purchase [# of shares] shares of Common Stock, $.001 par value, of Natio |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Com |
|
| November 4, 2021 |
NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2021 RESULTS Exhibit 99.1 1245 ?Q? Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2021 RESULTS LINCOLN, Nebraska (November 2, 2021) ? National Research Corporation (NASDAQ:NRC) today announced results for the third quarter of 2021. Financial Results (Q3 2021 compared to Q3 2020): ? |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nati |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commi |
|
| August 5, 2021 |
NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2021 RESULTS Exhibit 99.1 1245 ?Q? Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2021 RESULTS LINCOLN, Nebraska (August 3, 2021) ? National Research Corporation (NASDAQ:NRC) today announced results for the second quarter of 2021. Financial Results (Q2 2021 compared to Q2 2020): ? |
|
| July 21, 2021 |
NATIONAL RESEARCH CORPORATION 14,524,566 Shares of Common Stock Offered by Selling Shareholders Filed Pursuant to Rule 424(b)(7) Registration No. 333-232534 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated July 3, 2019) NATIONAL RESEARCH CORPORATION 14,524,566 Shares of Common Stock Offered by Selling Shareholders The following information amends and supplements information contained in the prospectus, dated July 3, 2019 (the ?Prospectus?). This Prospectus Supplement No. 1 should be read in |
|
| July 2, 2021 |
Exhibit 3.4 BYLAWS OF NATIONAL RESEARCH CORPORATION (a Delaware corporation) As amended through June 30, 2021 1 ARTICLE I. OFFICES 1.01. Principal and Business Offices. The Corporation may have such principal and other business offices, either within or without the State of Delaware, as the Board of Directors may designate or as the business of the Corporation may require from time to time. 1.02. |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 National Research Corporation (Exact name of registrant as specified in its charter) Delaware 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commis |
|
| July 2, 2021 |
Exhibit 3.2 |
|
| July 2, 2021 |
Exhibit 3.3 CERTIFICATE OF INCORPORATION OF NATIONAL RESEARCH CORPORATION (Effective June 30, 2021) ARTICLE 1 NAME The name of the corporation is National Research Corporation (the ?Corporation?). ARTICLE 2 REGISTERED OFFICE; REGISTERED AGENT The address of the Corporation?s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, County of New Castle |
|
| July 2, 2021 |
Exhibit 2.1 NATIONAL RESEARCH CORPORATION PLAN OF CONVERSION This Plan of Conversion, dated as of June 30, 2021 (this ?Plan?), of National Research Corporation, a Wisconsin corporation (the ?Company?), sets forth the terms, conditions, and procedures for the conversion of the Company from a Wisconsin corporation to a Delaware corporation pursuant to Sections 180.1161 and 180.1103 of the Wisconsin |
|
| July 2, 2021 |
Exhibit 3.1 |
|
| June 3, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commis |
|
| May 14, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| May 7, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nat |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commiss |
|
| May 5, 2021 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2021 RESULTS Exhibit 99.1 1245 ?Q? Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2021 RESULTS LINCOLN, Nebraska (May 4, 2021) ? National Research Corporation (NASDAQ: NRC) today announced results for the first quarter of 2021. As we emerge from the impact of COVID-19, our focus co |
|
| April 28, 2021 |
-12-31 FY 2020 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 9, 2021 |
NATIONAL RESEARCH CORPORATION DECLARES QUARTERLY DIVIDEND Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION DECLARES QUARTERLY DIVIDEND LINCOLN, Nebraska (April 9, 2021) — National Research Corporation (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payabl |
|
| April 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2021 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commi |
|
| March 22, 2021 |
EX-99.6 7 exhibit996.htm EXHIBIT 99.6 (POWER OF ATTORNEY OF COMMON PROPERTY TRUST LLC AND THOMAS RICHARDSON AS MANAGER OF COMMON PROPERTY TRUST LLC) Exhibit 99.6 POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitute and appoint each of Mark A. Scudder, Heidi Hornung-Scherr, and Christopher Kortum, signing singly, the undersigned's true and lawful attorney-in-fact to: |
|
| March 22, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, with respect to the shares of Common Stock, par value $.001 per share, of National Research Corporation, and any further amendments thereto executed by each and any of us shall be filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securitie |
|
| March 22, 2021 |
Exhibit 99.4 GUARANTY THIS GUARANTY (“Guaranty”) is made by AMANDLA LLC, a Delaware limited liability company (“Guarantor”), in favor of Bessemer Trust Company of Delaware, N.A., as Trustee of the K/I/E TRUST u/a dated October 24, 2018 (“Holder”), entered into and effective as of March 11, 2021. WHEREAS, Holder has made a loan (the “Loan”) to COMMON PROPERTY TRUST LLC, a Delaware limited liability |
|
| March 22, 2021 |
EX-99.3 4 exhibit993.htm EXHIBIT 99.3 (PROMISSORY NOTE ISSUED BY COMMON PROPERTY TRUST LLC, IN FAVOR OF BESSEMER TRUST COMPANY OF DELAWARE, N.A., AS TRUSTEE OF THE K/I/E TRUST UNDER AGREEMENT DATED OCTOBER 24, 2018) Exhibit 99.3 PROMISSORY NOTE US $242,327,622 March 11, 2021 FOR VALUE RECEIVED, the undersigned COMMON PROPERTY TRUST LLC, a Delaware limited liability company (the “Borrower”), hereby |
|
| March 22, 2021 |
Exhibit 99.5 POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitute and appoint each of Mark A. Scudder, Heidi Hornung-Scherr, and Christopher Kortum, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a stockholder of National Research Corporation (the "Company"), Sc |
|
| March 22, 2021 |
EX-99.2 3 exhibit992.htm EXHIBIT 99.2 (PURCHASE AGREEMENT, DATED MARCH 11, 2021, BY AND BETWEEN BESSEMER TRUST COMPANY OF DELAWARE, N.A., AS TRUSTEE OF THE K/I/E TRUST UNDER AGREEMENT DATED OCTOBER 24, 2018, AND COMMON PROPERTY TRUST LLC, A DELAWARE LIMITED LIABILITY COMPANY) Exhibit 99.2 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”) is dated March 11, 2021, between Bessemer Trust |
|
| March 22, 2021 |
SC 13D 1 schedule13d.htm SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 National Research Corporation (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Thomas Richardson Arnold & Porter Kaye Scholer LLP 601 Massachusetts Ave., NW Washington, D.C. 20001- |
|
| March 15, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, with respect to the shares of Common Stock, par value $.001 per share, of National Research Corporation, and any further amendments thereto executed by each and any of us shall be filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securitie |
|
| March 15, 2021 |
EX-99.2 3 exhibit992.htm EXHIBIT 99.2 (POWER OF ATTORNEY OF PATRICK E. BEANS, AS SPECIAL HOLDINGS DIRECTION ADVISER, AND K/I/E TRUST UNDER AGREEMENT 10/24/18) Exhibit 99.2 POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitute and appoint each of Mark A. Scudder, Heidi Hornung-Scherr, and Christopher Kortum, signing singly, the undersigned's true and lawful attorney-in |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Comm |
|
| March 15, 2021 |
SC 13D/A 1 schedule13da.htm SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 2) National Research Corporation (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Patrick E. Beans 709 Pier 2 Lincoln, NE 68528 402-440-2768 (Name, Address an |
|
| March 5, 2021 |
Subsidiary of National Research Corporation EX-21 2 ex228150.htm EXHIBIT 21 Exhibit 21 Subsidiary of National Research Corp. National Research Corporation’s subsidiary as of December 31, 2020 is listed below: Subsidiary Jurisdiction of organization National Research Corporation Canada Ontario |
|
| March 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 National |
|
| March 4, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 4) National Research Corporation (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Patrick E. Beans Amandla LLC 709 Pier 2 Lincoln, NE 68528 402-440-2768 (Name, Address and Telephone Number of Person Au |
|
| February 12, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 05)* NATIONAL RESEARCH CORP (Name of Issuer) Common Stock (Title of Class of Securities) 637372202 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 12, 2021 |
AGREEMENT JOINT FILING OF SCHEDULE 13G EX-1.2 2 ex992.htm EX-1.2 AGREEMENT JOINT FILING OF SCHEDULE 13G Kayne Anderson Rudnick Investment Management, LLC (an investment adviser registered under the Investment Advisers Act of 1940), and Virtus Investment Advisers, Inc. (an investment adviser registered under the Investment Advisers Act of 1940) and Virtus Equity Trust (on behalf of Virtus KAR Small-Cap Growth Fund), a Delaware statutory |
|
| February 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Co |
|
| February 11, 2021 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-TO-DATE 2020 RESULTS EX-99.1 2 ex225589.htm EXHIBIT 99.1 Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-TO-DATE 2020 RESULTS LINCOLN, Nebraska (February 9, 2021) — National Research Corporation (NASDAQ:NRC) (the “Company,” “we,” or “our”) today announced 202 |
|
| November 10, 2020 |
AGREEMENT JOINT FILING OF SCHEDULE 13G AGREEMENT JOINT FILING OF SCHEDULE 13G Kayne Anderson Rudnick Investment Management, LLC (an investment adviser registered under the Investment Advisers Act of 1940), and Virtus Investment Advisers, Inc. |
|
| November 10, 2020 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 04)* NATIONAL RESEARCH CORP (Name of Issuer) Common Stock (Title of Class of Securities) 637372202 (CUSIP Number) October 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 |
|
| November 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2020 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Co |
|
| November 3, 2020 |
EX-99.1 2 ex210937.htm EXHIBIT 99.1 Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER AND YEAR-TO-DATE 2020 RESULTS Net New Sales and Total Contract Value Continue Impressive Growth LINCOLN, Nebraska (November 3, 2020) — National Research Corporation |
|
| August 7, 2020 |
Exhibit 10.1 AMENDED AND RESTATED CREDIT AGREEMENT by and between NATIONAL RESEARCH CORPORATION, as Borrower, and FIRST NATIONAL BANK OF OMAHA, as Lender Dated as of May 28, 2020 THIS AMENDED AND RESTATED CREDIT AGREEMENT, dated as of May 28, 2020, is made and entered into by and between NATIONAL RESEARCH CORPORATION, a Wisconsin corporation (“Borrower”), and FIRST NATIONAL BANK OF OMAHA, a nation |
|
| August 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nati |
|
| August 7, 2020 |
Exhibit 10.2 FORM OF GRANT USED IN CONNECTION WITH THE NATIONAL RESEARCH CORPORATION 2004 NON-EMPLOYEE DIRECTOR STOCK PLAN, AS AMENDED [Director name] Re: Stock Option Grant National Research Corporation Director Stock Plan This letter is to confirm that on [date], you were automatically granted a nonqualified stock option to purchase [# of shares] shares of Common Stock, $.001 par value, of Natio |
|
| August 6, 2020 |
EX-99.2 3 ex197437.htm EXHIBIT 99.2 Exhibit 99.2 Thank you, , and welcome everyone to National Research Corporation’s 2020 second quarter earnings call. My name is Kevin Karas, the Company’s Chief Financial Officer. Before continuing, I would like to review conditions related to any forward-looking statements that may be made as part of today’s call. This conference call includes forward-looking s |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Comm |
|
| August 6, 2020 |
EX-99.1 2 ex197436.htm EXHIBIT 99.1 Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER AND YEAR-TO-DATE 2020 RESULTS Net New Sales and Total Contract Value Register Impressive Growth LINCOLN, Nebraska (August 4, 2020) — National Research Corporation |
|
| July 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2020 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commi |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2020 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commis |
|
| May 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2020 |
EX-3.1 2 ex186913.htm EXHIBIT 3.1 Exhibit 3.1 BY-LAWS OF NATIONAL RESEARCH CORPORATION (a Wisconsin corporation) As adopted September 15, 1997 As amended through May 15, 2020 ARTICLE I. OFFICES 1.01. Principal and Business Offices. The corporation may have such principal and other business offices, either within or without the State of Wisconsin, as the Board of Directors may designate or as the b |
|
| May 8, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 Nat |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commiss |
|
| May 7, 2020 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2020 RESULTS EX-99.1 2 ex185310.htm EXHIBIT 99.1 Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2020 RESULTS LINCOLN, Nebraska (May 5, 2020) — National Research Corporation (NASDAQ: NRC) today announced results for the first quarter of 2020. ● Revenue increase |
|
| May 7, 2020 |
EX-99.2 3 ex185311.htm EXHIBIT 99.2 Exhibit 99.2 Thank you, , and welcome everyone to National Research Corporation’s 2020 first quarter earnings call. My name is Kevin Karas, the Company’s Chief Financial Officer. I will be handling the call myself today from my home like most of you. Before continuing, I would like to review conditions related to any forward-looking statements that may be made a |
|
| April 7, 2020 |
NRC / National Research Corporation DEF 14A - - FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defini |
|
| March 23, 2020 |
Exhibit 3.1 BY-LAWS OF NATIONAL RESEARCH CORPORATION (a Wisconsin corporation) As adopted September 15, 1997 As amended through March 19, 2020 ARTICLE I. OFFICES 1.01. Principal and Business Offices. The corporation may have such principal and other business offices, either within or without the State of Wisconsin, as the Board of Directors may designate or as the business of the corporation may r |
|
| March 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2020 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Comm |
|
| March 6, 2020 |
NRC / National Research Corporation 10-K - Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35929 Nationa |
|
| March 6, 2020 |
Description of the Securities of the Registrant. Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, National Research Corporation (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $.001 (“Common Stock”). |
|
| March 6, 2020 |
EX-10.12 3 ex173630.htm EXHIBIT 10.12 Exhibit 10.12 FORM OF GRANT USED IN CONNECTION WITH THE NATIONAL RESEARCH CORPORATION 2004 NON-EMPLOYEE DIRECTOR STOCK PLAN, AS AMENDED [Director name] Re: Stock Option Grant National Research Corporation Director Stock Plan This letter is to confirm that on [date], you were automatically granted a nonqualified stock option to purchase [# of shares] shares of |
|
| March 6, 2020 |
Subsidiary of National Research Corporation EX-21 4 ex173631.htm EXHIBIT 21 Exhibit 21 Subsidiary of National Research Corp. National Research Corporation’s subsidiary as of December 31, 2019 is listed below: Subsidiary Jurisdiction of organization National Research Corporation Canada Ontario |
|
| February 13, 2020 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* NATIONAL RESEARCH CORP (Name of Issuer) Common Stock (Title of Class of Securities) 637372202 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 13, 2020 |
AGREEMENT JOINT FILING OF SCHEDULE 13G AGREEMENT JOINT FILING OF SCHEDULE 13G Kayne Anderson Rudnick Investment Management, LLC (an investment adviser registered under the Investment Advisers Act of 1940), and Virtus Investment Advisers, Inc. |
|
| February 13, 2020 |
NATIONAL RESEARCH CORPORATION ANNOUNCES 2019 FOURTH QUARTER AND YEAR-END RESULTS Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES 2019 FOURTH QUARTER AND YEAR-END RESULTS LINCOLN, Nebraska (February 11, 2020) — National Research Corporation (NASDAQ:NRC) today announced 2019 fourth quarter and year-end financial results. Fourth quarter 2019 co |
|
| February 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2020 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (C |
|
| February 13, 2020 |
Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation’s 2019 fourth quarter and year-end earnings call. My name is Mike Hays, the Company’s CEO and joining me on the call today is Linda Stacy, our VP of Finance and Steve Jackson, President. Before we continue, I would ask Linda to review conditions related to any forward-looking statements that may be made as part o |
|
| November 25, 2019 |
Exhibit 99.1 POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitute and appoint each of Mark A. Scudder, Heidi Hornung-Scherr, and Christopher Kortum, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a stockholder of National Research Corporation (the "Company"), Sc |
|
| November 25, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 3) National Research Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Patrick E. Beans Amandla LLC 709 Pier 2 Lincoln, NE 68528 402-440-2768 (Name, Address and Telephone Number of Person A |
|
| November 8, 2019 |
NRC / National Research Corporation 10-Q - Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| November 7, 2019 |
EX-99.2 3 ex163456.htm EXHIBIT 99.2 Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation’s 2019 third quarter earnings call. My name is Mike Hays, the Company’s CEO and joining me on the call today is Kevin Karas, our Chief Financial Officer. Before we continue, I would ask Kevin to review conditions related to any forward-looking statements that may be made as par |
|
| November 7, 2019 |
NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2019 RESULTS EX-99.1 2 ex163455.htm EXHIBIT 99.1 Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2019 RESULTS LINCOLN, Nebraska (November 5, 2019) — National Research Corporation (NASDAQ:NRC) today announced results for the third quarter of 2019. In comparison |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Co |
|
| August 8, 2019 |
NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2019 RESULTS EX-99.1 2 ex153805.htm EXHIBIT 99.1 Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2019 RESULTS LINCOLN, Nebraska (August 6, 2019) — National Research Corporation (NASDAQ:NRC) today announced results for the second quarter of 2019. ● Net New Sale |
|
| August 8, 2019 |
Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation’s 2019 second quarter earnings call. My name is Mike Hays, the Company’s CEO and joining me on the call today is Kevin Karas, our Chief Financial Officer. Before we continue, I would ask Kevin to review conditions related to any forward-looking statements that may be made as part of today’s call. Kevin. Kevin: Th |
|
| August 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Comm |
|
| August 8, 2019 |
NRC / National Research Corporation 10-Q - Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 |
|
| August 5, 2019 |
NRC / National Research Corporation CORRESP - - National Research Corporation 1245 Q Street Lincoln, Nebraska 68508 (402) 475-2525 August 5, 2019 VIA EDGAR Division of Corporation Finance Office of Beverages, Apparel and Mining U. |
|
| July 3, 2019 |
NRC / National Research Corporation S-3 - - FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on July 3, 2019 Registration No. |
|
| May 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2019 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2019 |
EX-99.2 3 ex143776.htm EXHIBIT 99.2 Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation’s 2019 first quarter earnings call. My name is Mike Hays, the Company’s CEO and joining me on the call today is Kevin Karas, our Chief Financial Officer. Before we continue, I would ask Kevin to review conditions related to any forward-looking statements that may be made as par |
|
| May 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2019 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2019 RESULTS Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2019 RESULTS LINCOLN, Nebraska (May 7, 2019) — National Research Corporation (NASDAQ: NRC) today announced results for the first quarter of 2019. ● Net New Sales of $4.1 million ● Net Income increased |
|
| May 8, 2019 |
NRC / National Research Corporation 10-Q Quarterly Report FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 |
|
| April 9, 2019 |
NRC / National Research Corporation FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defini |
|
| March 8, 2019 |
NRC / National Research Corporation FORM 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35929 Nat |
|
| March 8, 2019 |
Subsidiary of National Research Corporation Exhibit 21 Subsidiary of National Research Corp. National Research Corporation’s subsidiary as of December 31, 2018 is listed below: Subsidiary Jurisdiction of organization National Research Corporation Canada Ontario |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2019 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (C |
|
| February 14, 2019 |
Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation’s 2018 fourth quarter and year-end earnings call. My name is Mike Hays, the Company’s CEO and joining me on the call today is Kevin Karas, our Chief Financial Officer. Before we continue, I would ask Kevin to review conditions related to any forward-looking statements that may be made as part of today’s call. Kev |
|
| February 14, 2019 |
EX-99.1 2 ex134835.htm EXHIBIT 99.1 Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 2018 RESULTS Voice of Customer Platform Achieves Major Milestone LINCOLN, Nebraska (February 12, 2019) — National Research Corporation (NASDAQ:NRC) to |
|
| February 12, 2019 |
Exhibit 99.1 AGREEMENT JOINT FILING OF SCHEDULE 13G Kayne Anderson Rudnick Investment Management, LLC (an investment adviser registered under the Investment Advisers Act of 1940), and Virtus Investment Advisers, Inc. (an investment adviser registered under the Investment Advisers Act of 1940) and Virtus Equity Trust (on behalf of Virtus KAR Small-cap Growth Fund), a Delaware statutory trust, hereb |
|
| February 12, 2019 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* NATIONAL RESEARCH CORP (Name of Issuer) Common Stock (Title of Class of Securities) 637372202 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| November 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2018 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2018 |
NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2018 RESULTS EX-99.1 2 ex128737.htm EXHIBIT 99.1 Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2018 RESULTS LINCOLN, Nebraska (November 6, 2018) — National Research Corporation (NASDAQ:NRC) today announced results for the third quarter of 2018. ● Net New Sale |
|
| November 8, 2018 |
Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation’s 2018 third quarter earnings call. My name is Mike Hays, the Company’s CEO and joining me on the call today is Kevin Karas, our Chief Financial Officer. Before we continue, I would ask Kevin to review conditions related to any forward-looking statements that may be made as part of today’s call. Kevin. Kevin: Tha |
|
| November 8, 2018 |
NRC / National Research Corporation FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| August 9, 2018 |
NRC / National Research Corporation FORM S-8 As filed with the Securities and Exchange Commission on August 9, 2018 Registration No. |
|
| August 9, 2018 |
NRC / National Research Corporation FORM S-8 As filed with the Securities and Exchange Commission on August 9, 2018 Registration No. |
|
| August 9, 2018 |
National Research Corporation 2006 Equity Incentive Plan, as amended Exhibit 4.3 As Amended Effective as of April 17, 2018 NATIONAL RESEARCH CORPORATION 2006 EQUITY INCENTIVE PLAN Section 1. Purpose The purpose of the National Research Corporation 2006 Equity Incentive Plan (the “Plan”) is to promote the best interests of National Research Corporation (together with any successor thereto, the “Company”) and its shareholders by providing associates (i.e., employees) |
|
| August 9, 2018 |
Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2018 RESULTS Strong Market Adoption of Digital Voice of Customer (VOC) Platform LINCOLN, Nebraska (August 7, 2018) — National Research Corporation (NASDAQ:NRC) today announced results for the second |
|
| August 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2018 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Comm |
|
| August 9, 2018 |
Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation’s 2018 second quarter earnings call. My name is Mike Hays, the Company’s CEO. Joining me on the call today is Kevin Karas, our Chief Financial Officer. Before we continue, I would ask Kevin to review conditions related to any forward-looking statements that may be made as part of today’s call. Kevin. Kevin: Thank |
|
| August 9, 2018 |
NRC / National Research Corporation FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 |
|
| June 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2018 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commis |
|
| May 4, 2018 |
NRC / National Research Corporation FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 |
|
| May 3, 2018 |
Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation’s 2018 first quarter earnings call. My name is Mike Hays, the Company’s CEO. Joining me on the call today is Kevin Karas, our Chief Financial Officer. Before we continue, I would ask Kevin to review conditions related to any forward-looking statements that may be made as part of today’s call. Kevin. Kevin: Thank |
|
| May 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2018 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Commiss |
|
| May 3, 2018 |
EX-99.1 2 ex112416.htm EXHIBIT 99.1 Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2018 RESULTS Company Pivots Clients to Digital Voice of Customer (VOC) Platform LINCOLN, Nebraska (May 1, 2018) — National Research Corporation (NASDAQ: NRC) today |
|
| April 27, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defini |
|
| April 25, 2018 |
NRCIA / National Research Corp. / K/i/e/trust Under Agreement 3/9/09 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) National Research Corporation (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Kent E. Endacott Woods & Aitken LLP 301 S. 13th Street, Suite 500 Lincoln, Nebraska 68508 (402) 437-8500 (Name, Address an |
|
| April 25, 2018 |
NRCIA / National Research Corp. / Amandla Mk Trust Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) National Research Corporation (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 637372202 (CUSIP Number) Patrick E. Beans Amandla LLC 709 Pier 2 Lincoln, NE 68528 402-440-2768 (Name, Address and Telephone Number of Persons Auth |
|
| April 20, 2018 |
Exhibit 10 CREDIT AGREEMENT among NATIONAL RESEARCH CORPORATION, as Borrower, and FIRST NATIONAL BANK OF OMAHA, as Lender Dated as of April 18, 2018 CREDIT AGREEMENT, dated as of April 18, 2018, among NATIONAL RESEARCH CORPORATION, a Wisconsin corporation (“Borrower”), and FIRST NATIONAL BANK OF OMAHA, a national banking association (“Lender”). |
|
| April 20, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2018 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 001-35929 47-0634000 (State or other jurisdiction of incorporation) (Comm |
|
| April 20, 2018 |
NATIONAL RESEARCH CORPORATION ANNOUNCES CONSUMMATION OF CLASS B COMMON STOCK RECAPITALIZATION Exhibit 99 1245 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES CONSUMMATION OF CLASS B COMMON STOCK RECAPITALIZATION LINCOLN, Nebraska (April 17, 2018) — National Research Corporation (NASDAQ: NRCIA and NRCIB) today announced that its shareholders approved the December 2017 announced recapitalization plan pursuant to which each share of class B |
|
| April 20, 2018 |
EX-3.3 2 ex110590.htm EXHIBIT 3.3 Exhibit 3.3 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF NATIONAL RESEARCH CORPORATION (Effective April 17, 2018) Pursuant to Section 180.1007 of the Wisconsin Business Corporation Law, Chapter 180 of the Wisconsin Statutes, these amended and restated articles of incorporation of the corporation (the “corporation”), which corporation is organized under Chapte |
|
| April 18, 2018 |
NRCIA / National Research Corp. / National Research Corp - SCHEDULE 13E3/A As filed with the Securities and Exchange Commission on April 18, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 17, 2018 |
NRCIB / National Research Corp. FORM 15-12B united states securities and exchange commission Washington, D.C. 20549 form 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-29466 National Research Corporation (Exact name of registrant as specifi |
|
| April 17, 2018 |
NRCIB / National Research Corp. FORM 8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin (State of incorporation or organization) 47-0634000 (IRS Employer Identification N |
|
| April 17, 2018 |
NRCIB / National Research Corp. FORM 8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 2) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin (State of incorporation or organization) 47-0634000 (IRS Employer Identification N |
|
| March 14, 2018 |
NRCIB / National Research Corp. FORM 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35929 Nat |
|
| March 14, 2018 |
Subsidiary of National Research Corporation Exhibit 21 Subsidiary of National Research Corp. National Research Corporation’s subsidiary as of December 31, 2017 is listed below: Subsidiary Jurisdiction of organization National Research Corporation Canada Ontario |
|
| March 13, 2018 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 13, 2018 |
NRCIA / National Research Corp. / National Research Corp - SCHEDULE 13E3/A As filed with the Securities and Exchange Commission on March 13, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 23, 2018 |
NRCIB / National Research Corp. FORM PRER14A nrci20180124pre14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 4) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by R |
|
| February 23, 2018 |
EXHIBIT 2 PURCHASE AND SALE AGREEMENT THIS PURCHASE AND SALE AGREEMENT (this “Agreement”) is entered into as of this 15th day of February, 2018, by and between Michael D. |
|
| February 23, 2018 |
NRCIA / National Research Corp. / National Research Corp - SCHEDULE 13E3/A As filed with the Securities and Exchange Commission on February 23, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 23, 2018 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D as amended, with respect to the shares of Class A Common Stock, par value $. |
|
| February 23, 2018 |
EXHIBIT 3 PROMISSORY NOTE US $107,052,000 February 15, 2018 FOR VALUE RECEIVED, the undersigned Amandla II, LLC, a Delaware limited liability company, Patrick Beans, Manager (the “Borrower”), whose address is 709 Pier 2, Lincoln, NE 68528, hereby promises to pay to the order of Michael D. |
|
| February 23, 2018 |
NRCIA / National Research Corp. / Amandla Mk Trust Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) National Research Corporation (Name of Issuer) Class A Common Stock, $.001 par value Class B Common Stock, $.001 par value (Title of Class of Securities) 637372202 (Class A Common Stock) 637372301 (Class B Common Stock) (CUSIP Number) Patrick E. Beans Ama |
|
| February 23, 2018 |
NRC / National Research Corporation CORRESP ATTORNEYS AT LAW 777 East Wisconsin Avenue Milwaukee, WI 53202-5306 414.271.2400 TEL 414.297.4900 FAX www.foley.com WRITER’S DIRECT LINE 414.297.5668 [email protected] EMAIL CLIENT/MATTER NUMBER 044741-0103 February 23, 2018 Ms. Tiffany Piland Posil Special Counsel Office of Mergers and Acquisitions Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, D |
|
| February 23, 2018 |
EXHIBIT 4 February 23, 2018 VIA E-MAIL Board of Directors National Research Corporation 1245 Q Street Lincoln, Nebraska 68508 Ladies and Gentleman: The Amandla MK Trust (the "Trust") holds investments for the benefit of the family of Michael D. |
|
| February 22, 2018 |
NRCIA / National Research Corp. / Hays Michael D. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 23)* National Research Corporation (Name of Issuer) Class A Common Stock, $.001 par value Class B Common Stock, $.001 par value (Title of Class of Securities) 637372202 (Class A Common Stock) 637372301 (Class B Common Stock) (CUSIP Number) February 15, 2018 |
|
| February 16, 2018 |
nrci201802158k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2018 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 0-29466 47-0634000 (State or other jurisdiction of |
|
| February 16, 2018 |
EX-99.2 3 ex105366.htm EXHIBIT 99.2 Exhibit 99.2 Mike: Thank you, , and welcome everyone to National Research Corporation’s 2017 fourth quarter and year-end earnings call. My name is Mike Hays, the Company’s CEO. Joining me on the call today is Kevin Karas, our Chief Financial Officer. I would like to ask Kevin to review with us conditions regarding any forward looking statements that may be made |
|
| February 16, 2018 |
NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 RESULTS EX-99.1 2 ex105365.htm EXHIBIT 99.1 Exhibit 99.1 1245 “Q” Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 RESULTS LINCOLN, Nebraska (February 13, 2018) — National Research Corporation (NASDAQ: NRCIA and NRCIB) today announced results for the fourth qu |
